Disease/Condition
673 Clinical Trials
10+ Countries
Non-small Cell Lung Cancer Clinical Trials Database - Free Access to 673 Studies
Access comprehensive clinical trial information for Non-small Cell Lung Cancer through Pure Global AI's free database. This collection includes 673 clinical trials across multiple phases including Phase 2, N/A, Phase 3. Currently, 137 trials are actively recruiting participants.
Research for Non-small Cell Lung Cancer is being conducted in China, United States of America, South Korea and 7+ other countries. Leading sponsors include Sun Yat-sen University and AstraZeneca. Pure Global AI offers free access to clinical trial data from ClinicalTrials.gov, WHO ICTRP, and regional registries worldwide.
Free Database
Powered by Pure Global AI
840K+ Global Trials
Updated Daily
By Phase
Phase 2
272N/A
166Phase 3
89Phase 1
63Early Phase 1
46By Status
Completed
199Recruiting
137Unknown
133Not yet recruit...
89Terminated
55Top Countries
China248
United States of America118
South Korea28
Japan25
Canada16
Top Sponsors
Sun Yat-sen Univer...28
AstraZeneca18
Betta Pharmaceutic...14
Hunan Province Tum...13
Samsung Medical Ce...12
Recent Trials
Latest clinical trials for Non-small Cell Lung Cancer
NCT06406608
Recruiting
Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer
Henan Cancer HospitalChina
NCT06403111
Phase 2
Not yet recr...
FMT+Immunotherapy+Chemotherapy as First-line Treatment for Driver-gene Negative Advanced NSCLC
Changzhou No.2 People's Hospit...
NCT06388031
Phase 2
Not yet recr...
ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI
Peking Union Medical College H...China
NCT06382129
Phase 3
Not yet recr...
A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical C...China
NCT06382116
Phase 3
Not yet recr...
A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical C...China
NCT06370416
Phase 2
Not yet recr...
the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib
Henan Cancer HospitalChina
NCT06350097
Phase 3
Not yet recr...
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
AstraZenecaAustralia,China,South Korea,Taiwan
NCT06349252
Recruiting
Survival Validation and Gene Mutations of N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer
Fudan UniversityChina
NCT06355609
Phase 2
Not yet recr...
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW
Hunan Province Tumor HospitalChina
NCT06345729
Phase 3
Recruiting
A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)
Merck Sharp & Dohme LLCUnited States of America
NCT06331650
Phase 2
Recruiting
A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer
Guangzhou Institute of Respira...China
NCT06341660
Phase 2
Recruiting
To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)
Guangzhou Institute of Respira...China
NCT06341530
Phase 2
Recruiting
Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer
The First Affiliated Hospital ...China
NCT06322108
Phase 2
Not yet recr...
Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)
Immune Oncology Research Insti...Armenia
NCT06277674
Phase 2
Recruiting
Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI
Guangzhou University of Tradit...China
NCT06268210
Phase 2
Not yet recr...
Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer
Yonsei UniversitySouth Korea
NCT06295432
Phase 2
Recruiting
A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)
Dizal PharmaceuticalsChina
NCT06276283
Phase 2
Recruiting
DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
Dizal PharmaceuticalsChina
NCT06254599
Phase 3
Not yet recr...
A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Shouyao Holdings (Beijing) Co....China
NCT06232265
Recruiting
An Observational Study on Predicting the Efficacy of Immunotherapy for NSCLC Based on LIRAscore
Nanfang Hospital, Southern Med...China
About Non-small Cell Lung Cancer Research
Pure Global AI provides free access to 673 clinical trials studying Non-small Cell Lung Cancer, aggregated from major global registries including ClinicalTrials.gov, WHO ICTRP, and regional databases.
The trials span multiple phases, from early Phase 1 safety studies to large-scale Phase 3 efficacy trials, conducted across 10+ countries.
Top research sponsors include Sun Yat-sen University, AstraZeneca, Betta Pharmaceuticals Co., Ltd., among others.
Quick Facts
Total Trials673
Countries10+
Sponsors10+
Recruiting137